Hollie Burrell-Saward1, Jean Rodgers2, Barbara Bradley3, Simon L Croft1, Theresa H Ward4. 1. Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK. 2. Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1QH, UK. 3. Institute of Infection and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1QH, UK. 4. Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK theresa.ward@lshtm.ac.uk.
Abstract
OBJECTIVES: To optimize the Trypanosoma brucei brucei GVR35 VSL-2 bioluminescent strain as an innovative drug evaluation model for late-stage human African trypanosomiasis. METHODS: An IVIS® Lumina II imaging system was used to detect bioluminescent T. b. brucei GVR35 parasites in mice to evaluate parasite localization and disease progression. Drug treatment was assessed using qualitative bioluminescence imaging and real-time quantitative PCR (qPCR). RESULTS: We have shown that drug dose-response can be evaluated using bioluminescence imaging and confirmed quantification of tissue parasite load using qPCR. The model was also able to detect drug relapse earlier than the traditional blood film detection and even in the absence of any detectable peripheral parasites. CONCLUSIONS: We have developed and optimized a new, efficient method to evaluate novel anti-trypanosomal drugs in vivo and reduce the current 180 day drug relapse experiment to a 90 day model. The non-invasive in vivo imaging model reduces the time required to assess preclinical efficacy of new anti-trypanosomal drugs.
OBJECTIVES: To optimize the Trypanosoma brucei brucei GVR35 VSL-2 bioluminescent strain as an innovative drug evaluation model for late-stage human African trypanosomiasis. METHODS: An IVIS® Lumina II imaging system was used to detect bioluminescent T. b. brucei GVR35 parasites in mice to evaluate parasite localization and disease progression. Drug treatment was assessed using qualitative bioluminescence imaging and real-time quantitative PCR (qPCR). RESULTS: We have shown that drug dose-response can be evaluated using bioluminescence imaging and confirmed quantification of tissue parasite load using qPCR. The model was also able to detect drug relapse earlier than the traditional blood film detection and even in the absence of any detectable peripheral parasites. CONCLUSIONS: We have developed and optimized a new, efficient method to evaluate novel anti-trypanosomal drugs in vivo and reduce the current 180 day drug relapse experiment to a 90 day model. The non-invasive in vivo imaging model reduces the time required to assess preclinical efficacy of new anti-trypanosomal drugs.
Authors: Mark C Field; David Horn; Alan H Fairlamb; Michael A J Ferguson; David W Gray; Kevin D Read; Manu De Rycker; Leah S Torrie; Paul G Wyatt; Susan Wyllie; Ian H Gilbert Journal: Nat Rev Microbiol Date: 2017-02-27 Impact factor: 60.633
Authors: Paula MacGregor; Andrea L Gonzalez-Munoz; Fatoumatta Jobe; Martin C Taylor; Steven Rust; Alan M Sandercock; Olivia J S Macleod; Katrien Van Bocxlaer; Amanda F Francisco; Francois D'Hooge; Arnaud Tiberghien; Conor S Barry; Philip Howard; Matthew K Higgins; Tristan J Vaughan; Ralph Minter; Mark Carrington Journal: PLoS Negl Trop Dis Date: 2019-05-23
Authors: Dennis C Koester; Vanessa M Marx; Sarah Williams; Jan Jiricek; Maxime Dauphinais; Olivier René; Sarah L Miller; Lei Zhang; Debjani Patra; Yen-Liang Chen; Harry Cheung; Jonathan Gable; Suresh B Lakshminarayana; Colin Osborne; Jean-Rene Galarneau; Upendra Kulkarni; Wendy Richmond; Angela Bretz; Linda Xiao; Frantisek Supek; Christian Wiesmann; Srinivas Honnappa; Celine Be; Pascal Mäser; Marcel Kaiser; Ryan Ritchie; Michael P Barrett; Thierry T Diagana; Christopher Sarko; Srinivasa P S Rao Journal: J Med Chem Date: 2022-08-22 Impact factor: 8.039
Authors: Éva Dóró; Sem H Jacobs; Ffion R Hammond; Henk Schipper; Remco Pm Pieters; Mark Carrington; Geert F Wiegertjes; Maria Forlenza Journal: Elife Date: 2019-09-24 Impact factor: 8.140